@article{2b0fc73172fd40108b35561280fe8f97,
title = "Which antihypertensive treatment is better for mild to moderate hypertension in pregnancy?",
keywords = "Antihypertensive Agents/therapeutic use, Female, Humans, Hypertension, Pregnancy-Induced/drug therapy, Labetalol/therapeutic use, Methyldopa/therapeutic use, Nifedipine/therapeutic use, Pregnancy, Prenatal Care/methods, Treatment Outcome",
author = "Danielle Ashworth and Cheryl Battersby and Marcus Green and Pollyanna Hardy and McManus, {Richard J.} and Catherine Cluver and Chappell, {Lucy C.}",
note = "Funding Information: Competing interests: We have read and understood the BMJ Group policy on declaration of interests and declare the following interests: CB is co-investigator for the Giant PANDA study and supported by the National Institute for Health Research through a fellowship award; MG and PH are co-investigators for the Giant PANDA study; RJM is co-investigator on the Giant PANDA study, has received blood pressure monitors for research from Omron, and his institution receives payments from licensing and consultancy from Omron and Sensyne for the development of telemonitoring systems; LCC is lead",
year = "2022",
month = jan,
day = "18",
doi = "10.1136/bmj-2021-066333",
language = "English",
volume = "376",
journal = "The BMJ",
issn = "0959-8146",
}